Sarepta fell over 1% premarket after the US Food and Drug Administration (FDA) added a boxed warning to its $3.2 million gene therapy Elevidys following two pediatric deaths. The agency also restricted use to ambulatory patients aged four and older, sharply shrinking the eligible market. The setback follows a failed trial and weaker Elevidys revenue, compounding pressure on the company.